What are the main drivers of type 2 diabetes (T2D) and why does the diabetes epidemic continue to grow despite a wealth of information? Join series host Dr John Anderson, past president of ADA, who practices internal medicine at the Frist Clinic, as he interviews fellow experts on the main drivers of T2D and how clinicians can optimize patient outcomes in this changing disease area.
This podcast is sponsored and developed by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.
EPISODE 1:
What is the burden of the type 2 diabetes (T2D) epidemic? Join experts in T2D: Dr John Anderson (primary care provider), Dr Susan Cornell (clinical pharmacist and certified diabetes care and education specialist) and Dr Doron Schneider (primary care provider) as they discuss the physical, emotional, psychological and economic burden of T2D and its comorbidities on the US healthcare system and on their patients and what they, as clinicians need to do to ease this burden.
- John E. Anderson, MD
- Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES
- Doron Schneider, MD, MBA, FACP
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
EPISODE 2:
What do you know about the role of beta-cell dysfunction in the pathophysiology of type 2 diabetes (T2D)?
Join primary care experts in T2D: Dr John Anderson, Dr Stephen Brunton and Dr James LaSalle as they discuss the beta-cell function and its critical role in T2D pathogenesis, what clinicians know or should know about it and how it is measured in the clinic, and how our current knowledge of beta-cell function in T2D may affect future research on T2D treatment.
- John E. Anderson, MD
- Stephen Brunton, MD, FAAFP
- James LaSalle, DO, FAAFP
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
EPISODE 3:
What is the role of endogenous GLP-1 in the pathophysiology of T2D? Join multidisciplinary experts in T2D: Dr John Anderson, Dr Vivian Fonseca, and Dr Jim Gavin as they discuss the history of GLP-1 discovery and the role of endogenous GLP-1 in the pathophysiology of T2D.
- John E. Anderson, MD
- Vivian A. Fonseca, MD, FRCP
- James R. Gavin III, MD, PhD
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
EPISODE 4:
What is the impact of insufficient GLP-1 activity in type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson, Dr Javier Morales, and Dr Richard Pratley as they review the role of GLP-1 in glucose regulation, consider the impact of insufficient GLP-1 activity on pancreatic beta cells in patients with T2D, and discuss possibilities to overcome insufficient GLP-1 activity in patients with T2D.
John E. Anderson, MD
Javier Morales, MD, FACP, FACE
Richard Pratley, MD
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
EPISODE 5:
- John E. Anderson, MD
- Pam Taub, MD, FACC
- Mark Greathouse, MD
EPISODE 6:
Join episode host, Todd Eury (founder and CEO of Pharmacy Podcast Network), as he discusses the indispensable role of pharmacists in T2D care with Diana Isaacs (endocrine clinical pharmacist), and Rohit Moghe (ambulatory care & and population health clinical pharmacist). These pharmacist experts will share insights on why the role of pharmacists is so important in T2D care, including reviewing data on how pharmacist involvement improves measurable outcomes for patients with T2D. To raise awareness, they will also review T2D treatment recommendations from major medical societies.
- Todd Eury, BS,
- Rohit Moghe, PharmD, MSPH, CDCES
- Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
EPISODE 7:
Should we be thinking differently about type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson (primary care provider), Ms Lucia Novak (nurse practitioner), and Dr Joshua Stolker (cardiologist) as they talk about ways to think differently about type 2 diabetes.
They will discuss factors in addition to A1C such as comorbidities, recommendations on managing patients with T2D from national endocrinology and cardiology societies, and how the cardiology community can work with the diabetology community to provide the best care for patients with T2D.
- John E. Anderson, MD
- Lucia M. Novak, MSN, ANP-BC, BC-ADM
- Joshua M. Stolker, MD
This podcast is sponsored by Novo Nordisk and is intended for clinicians.
